How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | BIIBBIOGEN INC. | REGNREGENERON PHARMACEUTICALS, INC. | MRNAModerna, Inc. | NTRANatera, Inc. | Median of the restexcluding BIIB |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $240.98▼ 2.12 (0.87%) | $805.67▼ 1.81 (0.22%) | $245.81▲ 3.73 (1.54%) | $401.37▼ 12.01 (2.91%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 9.0/10 | 8.7/10 | 6.0/10 | 4.7/10 | 6.0/10 |
| Market value | $35.38B | $84.27B | $96.85B | $56.07B | |
| Revenue | $9.89B | $14.34B | $1.94B | $2.31B | |
| Profit | $1.29B | $4.50B | -$2.82B | -$208.2M | |
| Revenue growthChange in sales versus the prior year. | 2.2% | 1.0% | -39.9% | 35.9% | 1.0% |
| Gross marginShare of sales left after the direct cost of producing them. | 75.7% | — | 55.3% | — | 55.3% |
| Operating marginShare of sales left after running the business, before interest and tax. | — | 24.9% | -158.1% | -13.4% | -13.4% |
| Profit marginProfit kept from each dollar of sales. | 13.1% | 31.4% | -145.2% | -9.0% | -9.0% |
| Free cash flow marginCash left after capital spending, as a share of sales. | 20.7% | 28.4% | -106.2% | 4.7% | 4.7% |
| Return on equityProfit against the owners' stake in the company. | 7.1% | 14.4% | -32.6% | -12.2% | -12.2% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | — | 10.2% | -36.5% | -34.2% | -34.2% |
| P/E ratioPrice paid per dollar of annual profit. | 27.36x | 18.71x | — | — | 18.71x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | — | 20.17x | — | — | 20.17x |
| Price to book | 1.94x | 2.70x | 11.20x | 32.74x | 11.20x |
| Debt to equityTotal liabilities compared with owners' stake. | 0.61x | 0.30x | 0.43x | 0.40x | 0.40x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 6/9 | 6/8 | 3/9 | 2/7 | 3.0 |
| Bankruptcy riskAltman Z-Score zone. | safe | safe | safe | distress |
How BIIB compares with the others
- BIIB's profit margin of 13.1% is higher than the median of the other companies selected (-9.0%).
- Its revenue growth of 2.2% is in line with the median of the other companies selected (1.0%).
- It trades at a higher P/E than the other company selected: 27.4x against 18.7x.
- Its liabilities are higher relative to equity than the median of the other companies selected: 0.6x against 0.4x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.